SM
ARRY

Sabby Management’s Array Biopharma Inc ARRY Stock Holding History

Sabby Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,500
Closed -$2.09M – 239
2017
Q2 		$2.09M Hold
2,500
– – 0.14% 67
2017
Q1 		$2.23M Buy
+2,500
New +$26.6K 0.12% 84

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Sabby Management's ARRY Position: Q3 2017 in Review

Sabby Management sold out of Array Biopharma Inc (ARRY) in Q3 2017, closing a stake of 155,757 shares — an estimated $1.3M sold.

Sabby Management first reported a position in ARRY in Q1 2017 and held it in 2 quarters. The position peaked at $1.4M in Q1 2017. 184 funds tracked by Wall St. Rank hold ARRY as of Q3 2017.

  • Sabby Management reported no remaining Array Biopharma Inc position as of Q3 2017 after selling out during the quarter.
  • Sabby Management sold 155,757 Array Biopharma Inc shares in Q3 2017, an estimated $1.3M.
  • Sabby Management first reported a position in Array Biopharma Inc in Q1 2017 and held it in 2 quarters.
  • Sabby Management's Array Biopharma Inc position peaked at $1.4M in Q1 2017.
  • 184 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2017.

Based on Sabby Management's 13F filing for Q3 2017, filed 14 Nov 2017.